Category Archives: Business of Biotech

Choose Wisely My Friend- Survey Says, Identifying the Right R&D Partner is the Most Challenging Aspect of Outsourcing Market

b9e35848296c8b6718258607ece28d99

A recent survey conducted by BIO confirms the increasing reliance on R&D outsourcing as biotech and pharmaceutical companies indicate speed, flexibility, and access to specialized resources drive pipeline strategies/decisions.  Despite these biopharma companies having veteran teams with outsourcing experience, our survey results help quantify inefficiencies facing nearly every relevant organization. The survey polled a group of small biotech companies about their experience with CROs and other contract service providers.  Over 80% of the companies surveyed were actively outsourcing portions of their pre-clinical or clinical pipelines.  Nearly two-thirds of the companies surveyed dedicated more than 20% of their entire budget to these services in 2014.  In addition, every company surveyed plans on maintaining Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,

Don’t Go At It Alone- BIO BizLink and the Evolving R&D Marketplace

b9e35848296c8b6718258607ece28d99

With companies in the biotechnology industry more frequently outsourcing R&D pipelines, selecting the right contract organization becomes more important. BIO, along with OnDeckBiotech, has recently launched a new online platform, BIO BizLink, that facilitates these relationships between biopharma companies and contract service providers. BIO BizLink serves as a peer-rated database for contract manufacturing organizations (CMOs) and contract research organizations (CROs) and their specific capabilities, while additionally providing secure project management tools to help companies work Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,

BIO Investor Forum Closing Plenary: How Fragile is the Biotech Rally After Five Positive Years?

2

Last week’s 13th Annual BIO Investor Forum closed on Wednesday with a plenary session asking, “How fragile is the biotech rally after five positive years?” Moderated by Todd Foley, Managing Director, MPM Capital, the panel included: Rachel King, CEO, GlycoMimetics and Chair, BIO Ellen Lubman, VP Strategy and Innovation, Forest Laboratories Vijay Murthy, Director, Ventures and Early Stage Collaborations, AbbVie Michael A. Margolis, RPh, Managing Director, ROTH Capital Partners Doug Fambrough, PhD, CEO, Dicerna Pharmaceuticals Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , ,

Biotech CEOs Talk JOBS Act and IPO Experiences at 2014 BIO Investor Forum

Biotech IPOs Infographic

The JOBS Act has contributed to a dramatic acceleration in new biotech IPOs since its passage, with nearly a tripling in the rate of companies going public in the industry. By changing how entrepreneurs can access and communicate with investors earlier in the process, the JOBS Act has fundamentally shifted how CEOs of discovery-driven companies must spend their time dealing with internal versus external priorities. Yesterday at the 2014 BIO Investor Forum, a panel of Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

NCATS SBIR Announces Funding For Biotechs and Small Business Technology Development

lab_tech

The NIH National Center for Advancing Translational Sciences (NCATS) is seeking qualified applicants for its Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. NCATS, which offers $17.6 million annually through these programs, has issued a call for applications for two funding opportunities: Contract funding to support small businesses and venture-backed technology development, due Nov. 5, 2014. Investigator-initiated grant funding,due Dec. 5, 2014. NCATS’ SBIR and STTR programs are engines of innovation Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,